Palomino Laboratories (PALX) EBT (2023 - 2025)
Palomino Laboratories (PALX) posted EBT of -$1.6 million for Q3 2025, down 3568.44% sequentially from -$43775.0 in Q2 2025, and down 143536.85% YoY from N/an in Q3 2024.
Palomino Laboratories (PALX) EBT (2023 - 2025) Analysis & Trends
Palomino Laboratories has reported EBT for 3 years, with the latest figure at -$1.6 million in Q3 2025.
- Quarterly EBT fell 143536.85% year-over-year to -$1.6 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was -$1.8 million (down 893.59% YoY) and the FY2024 annual result came in at -$145866.0, down 22.73% from the prior year.
- EBT retreated to -$1.6 million in Q3 2025 per PALX's latest filing, from -$43775.0 in the prior quarter.
- Over five years, EBT peaked at -$1118.0 in Q3 2024 and troughed at -$1.6 million in Q3 2025.
- A 3-year average of -$226325.9 and a median of -$51304.0 in 2024 frame the typical range for EBT.
- The sharpest annual moves came in 2024 and 2025: EBT jumped 97.39% in 2024, then tumbled 143536.85% in 2025.
- Over 3 years, EBT stood at -$67487.0 in 2023, then slumped by 102.91% to -$136938.0 in 2024, then sank by 1072.69% to -$1.6 million in 2025.
- According to Business Quant data, EBT over the past three periods registered -$1.6 million, -$43775.0, and -$25156.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -1.61 Mn |
| Jun 30, 2025 | -43,775.00 |
| Mar 31, 2025 | -25,156.00 |
| Dec 31, 2024 | -136,938.00 |
| Sep 30, 2024 | -1,118.00 |
| Jun 30, 2024 | -62,432.00 |
| Mar 31, 2024 | -51,304.00 |
| Dec 31, 2023 | -67,487.00 |
| Sep 30, 2023 | -42,863.00 |